Improved insulin sensitivity, nutrient partitioning, and signal for hepatic fat burn would still happen absent the "hunger" signal associated primarily with GLP-1 and thus still be working.
Cagri hitting on Amylin does make me think that Eli, Novo, or Pfizer will probably end up making a quad agonist that covers GLP-1/GIP/Glucagon/Amylin as it seems like a no-brainer given CagriSema is going to fare well and some of the vendors starting to mix reta and cagri.
CN vendors, figure out an oral MK677/orforglipron combo.